Compare FINV & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FINV | ZVRA |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | China | United States |
| Employees | 3869 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 739.0M | 689.4M |
| IPO Year | 2017 | 2015 |
| Metric | FINV | ZVRA |
|---|---|---|
| Price | $3.07 | $11.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $12.10 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 1.0M | 774.2K |
| Earning Date | 05-19-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.09% | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 0.74 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | N/A | $37.27 |
| Revenue Next Year | $10.58 | $53.42 |
| P/E Ratio | ★ $3.87 | $14.93 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $3.10 | $8.01 |
| 52 Week High | $7.65 | $15.04 |
| Indicator | FINV | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 27.40 | 39.00 |
| Support Level | N/A | $10.81 |
| Resistance Level | $3.49 | $12.19 |
| Average True Range (ATR) | 0.11 | 0.40 |
| MACD | 0.02 | -0.11 |
| Stochastic Oscillator | 10.47 | 12.54 |
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.